SMA
IBER.U

Sage Mountain Advisors’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Sage Mountain Advisors’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,200
Closed -$132K – 384
2022
Q4 		$132K Sell
13,200
-820
-6% -$8.18K 0.03% 183
2022
Q3 		$139K Sell
14,020
-64,910
-82% -$643K 0.04% 208
2022
Q2 		$774K Sell
78,930
-2,130
-3% -$21K 0.14% 127
2022
Q1 		$794K Sell
81,060
-8,120
-9% -$80.8K 0.12% 155
2021
Q4 		$894K Sell
89,180
-1,920
-2% -$19.1K 0.11% 167
2021
Q3 		$911K Sell
91,100
-2,370
-3% -$23.6K 0.13% 142
2021
Q2 		$939K Hold
93,470
– – 0.16% 127
2021
Q1 		$922K Buy
+93,470
New +$935K 0.2% 87

Sage Mountain Advisors's IBER.U Position: Q1 2023 in Review

Sage Mountain Advisors sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2023, closing a stake of 13,200 shares — an estimated $132K sold.

Sage Mountain Advisors first reported a position in IBER.U in Q1 2021 and held it in 8 quarters. The position peaked at $939K in Q2 2021. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

  • Sage Mountain Advisors reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2023 after selling out during the quarter.
  • Sage Mountain Advisors sold 13,200 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2023, an estimated $132K.
  • Sage Mountain Advisors first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 8 quarters.
  • Sage Mountain Advisors's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $939K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2023.

Based on Sage Mountain Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.